G LP-1RAs (glucagon-like peptide-1 receptor agonists) mimic the effects of the native gut-derived incretin hormone GLP-1 and are now routinely used as glucoselowering drugs in type 2 diabetes mellitus (T2DM) management. 1 GLP-1RAs can be categorized as either short-acting compounds, which provide short-lived receptor-activation, or as long-acting compounds, which continuously activate GLP-1R (GLP-1 receptors). 1 The differences in pharmacokinetic profiles translate into different clinical actions. For instance, short-acting GLP-1RAs predominantly lower postprandial glucose excursions by slowing gastric emptying rate (GER) and reducing intestinal glucose uptake and glucagon release, whereas long-acting GLP-1RAs have stronger effects on fasting glucose levels mediated predominantly by their insulinotropic actions. 1 Consistent with the wide distribution of the GLP-1R, GLP-1RAs are known to exhibit multiple extrapancreatic effects, including actions on the heart and blood vessels. 2 Immediate administration of GLP-1 or a GLP-1RA increases fasting blood pressure (BP) in many human studies. [3] [4] [5] [6] [7] [8] [9] In contrast, prolonged GLP-1RA treatment in T2DM patients is generally associated with lowering of fasting BP 10 by ≈1.8 to 4.6 mm Hg. 11 Underlying mechanisms remain unclear, yet may involve bodyweight-lowering, natriuresis/diuresis, endothelial-dependent/independent vasodilation, decreased arterial stiffness, and reduced renin-angiotensin-aldosterone system activity. 10, 12 Although humans spent most of diurnal time in the postprandial state, the effects of GLP-1RA treatment on BP after meal ingestion remains largely unstudied. In T2DM patients, immediate infusion of GLP-1 13 or GLP-1RA exenatide 14 attenuated the BP lowering response to orally administered glucose or a mixed meal, respectively. Several mechanisms are proposed to explain this effects. As such, the GLP-1RA-induced reduction in GER may prevent a postprandial BP fall by slowing the passage rate of nutrients to the small intestine, 13, 14 and by increasing vascular resistance in muscles through gastric distension (the so-called gastrovascular reflex). [13] [14] [15] [16] [17] Moreover, increased cardiac output, 18 sympathetic nervous system (SNS) activity 19 and vascular stiffness, 20 and reduced insulin-mediated vasodilation 1, 14, 16 may play part. Postprandial BP augmentation is of interest as observational studies suggest that postprandial hypertension is associated with atherosclerosis. 21 However, it is unclear whether the increase in postprandial BP with GLP-1RAs is sustained over time. We demonstrated that the long-acting GLP-1RA liraglutide does not affect repeatedly measured postprandial BP and systemic hemodynamic functions in T2DM patients after 12 weeks of treatment. 14 In contrast to liraglutide, we recently showed that 8-week treatment with lixisenatide, a prandial short-acting GLP-1RA, increases postbreakfast BP at a single postmeal time point in overweight T2DM patients compared with once-daily titrated insulin glulisine (iGlu). 12 In the current secondary analysis of this trial, we aimed to further detail the effects of lixisenatide on fasting and postprandial BP responses, and explore potential mechanisms that drive changes in BP. We hypothesized that prolonged lixisenatide treatment compared with iGlu increases postbreakfast BP by reducing GER and circulating glucose and insulin concentrations, leading to raised systemic vascular resistance (SVR) and arterial stiffness, and by increasing cardiac output.
Methods

Trial Design
The data that support the findings of this study are available from the corresponding author on reasonable request. This was a prespecified secondary analysis of a phase-4, monocenter, randomized, openlabel, comparator-controlled, parallel-group, intervention trial, which was primarily designed to determine the effects of lixisenatide versus once-daily titrated iGlu on renal physiology; design and detailed methods have been published previously. 12 After a run-in period of 4 weeks, during which antihyperglycemic treatment was not changed, subjects were randomized and entered an intervention period of 8 weeks. After week 4, a safety visit was performed. The study protocol, protocol amendments, and any other protocol-specific documents were approved by the ethics review board of the VU University Medical Center (Amsterdam, The Netherlands) and local authorities. The study complied with the Declaration of Helsinki and Good Clinical Practice guidelines and was registered at URL: http://www. clinicaltrials.gov. Unique identifier: NCT02276196.
Study Population
Eligible patients were white men or postmenopausal women, aged 35 to 75 years with T2DM and a body mass index >25 kg/m 2 . Patients were treated with basal insulin glargine, with or without metformin. BP needed to be controlled (ie, <140/90 mm Hg) and treatment for hypertension and albuminuria included a renin-angiotensin system (RAS) inhibition. Exclusion criteria included a recent (<6 months) history of cardiovascular disease (including acute coronary syndrome, heart failure, or stroke), complaints compatible with gastroparesis or the use of diuretics that could not be stopped 3 months before and during the intervention period.
Details of the randomization process and interventions are contained in the Methods in the online-only Data Supplement.
End Point Measurements
Patients were instructed to control their intake of sodium (9-12 g/d) 2 days before to testing procedures, to abstain from vigorous physical activity and alcohol ingestion for ≥24 hours, and to withhold from nicotine or caffeine for ≥12 hours. Patients arrived in the fasting state and delayed all morning medications with the exception of metformin and thyroid hormone replacement therapy. A venous cannula was inserted in an antecubital vein of the nondominant arm for venous blood sampling. All measurements were performed after a quiet rest period of at least 10 minutes in supine position, and at the nondominant arm, which was placed comfortably at heart level. Appropriate cuff sizes were used were applicable.
Measurements were performed ≈85 to 50 minutes before, and repeated up to 175 minutes after a standardized mixed breakfast, which consisted of bread with cheese and jam, and milk (416 kcal; 14 g fat; 48 g carbohydrates; and 22 g protein). Together with the meal, 1.5 g of acetaminophen in suspension form was administered to determine GER. 12 After the fasting measurements at week 8, patients injected lixisenatide or iGlu 30 and 10 minutes before breakfast, respectively. To stimulate diuresis for the renal tests that were performed concurrently, 12 patients consumed 500 mL of tap water before arriving at the clinical research unit and 10 mL/kg (maximum 1000 mL) of tap water in 2 equal parts just prior and ≈40 minutes after the meal, followed by 150 mL ≈70 and ≈115 minutes postprandially. Fasting blood samples were analyzed for HbA 1c , plasma glucose, hematocrit, creatinine, and renin-angiotensin-aldosterone system hormones (ie, plasma renin concentration, angiotensin II, and aldosterone). Renin-angiotensinaldosterone system hormones and hematocrit were also determined 105 and 115 minutes after the meal, respectively. Catecholamines (ie, noradrenaline, adrenaline, and dopamine) were determined 105 minutes postprandially whereas blood glucose, acetaminophen (as indicated in Figure 5 ), insulin, and C-peptide levels were measured throughout the testing day. 12 After randomization, patients were instructed to consume a daily breakfast with a comparable composition as offered during the testing day to titrate iGlu.
BP and Heart Rate
Systolic BP (SBP), diastolic BP (DBP), and heart rate (HR) were measured by a trained observer using an automatic oscillometric device (Dinamap, GE Healthcare, Little Chalfont, United Kingdom). Measurements were performed in triplicate at 1 to 2-minute intervals and the mean of the last 2 measurements was used for each time point (Figures 1 and 3) . 22 If the second and third measurement were discrepant, a fourth measurement was taken. 22 The overall postbreakfast SBP and DBP were the end points of primary interest. For safety, patients returned to the clinical research unit at week 4, during which fasting BP and HR were also measured
Systemic Hemodynamic Functions
Stroke volume (SV), cardiac output, and SVR were calculated noninvasively by a beat-to-beat finger arterial photoplethysmography BP monitoring device (Nexfin, Amsterdam, The Netherlands). SV, cardiac output, and SVR were normalized for body surface area, to acquire SV index (SVI), cardiac index (CI), and SVR index (SVRI), respectively. The finger BP measurements were performed over a period of 30 seconds, and a mean was derived using dedicated software (Nexfin@PC version 2.0, BM Eye, Amsterdam, The Netherlands). The within-day and between-day variability of these assessments are ≤9.1%. August 2018
Pulse Wave Analysis
Pulse wave analysis was performed at the level of the radial artery using applanation tonometry with a high-fidelity micromanometer (SPT-301, Millar Instruments, Houston, TX) coupled to a SphygmoCor apparatus and version 6.31 software (Atcor Medical Pty Ltd, West Ryde, Australia). The average of 2 measurements of ≥12 seconds was used, which needed to have adequate pulse wave profiles and high-quality control, defined as an in-device quality index of >80%. The central aortic pressure waveform was derived from the radial artery waveform using the software's mathematical transfer function. 23, 24 The augmentation index (an indicator of arterial stiffness) was calculated as the augmentation pressure, that is, the pressure of the second systolic peak minus the pressure at the inflection point, expressed as percentage of the pulse pressure and normalized for an HR of 75 bpm (augmentation index normalized to heart rate of 75 bpm [AIX@HR75]).
HR Variability
Using an ECG-equipped Nexfin device, 5-minute RR-interval recordings were obtained, during which patients were instructed to breath spontaneously (range, 10-18 breaths/min) and to refrain from sleeping or speaking. ECG measurements were visually inspected and artifacts were manually corrected using linear interpolation. ECG recordings were loaded into Kubios heart rate variability analysis software 2.2 (University of Eastern Finland, Biosignal Analysis and Medical Imaging Group, Kuopio, Finland). After additional automated low level artifact correction and removal of trend components (smoothn priors setting), fast Fourier spectral analyses were performed to obtain normalized low frequency (LF, 0.04-0.15 Hz) and high frequency (HF, 0.15-0.5 Hz) bands, from which the LF/ HF ratio, a validated marker for cardiac sympathovagal balance, 9 was calculated.
Autonomic nerve function testing, body impedance analysis (for assessment of body fat and body water), and laboratory analyses are described in the Methods in the online-only Data Supplement.
Calculations, Data Management, and Statistical Analyses
As current data are part of a larger study, of which the mechanistic effects on systemic hemodynamics were added as secondary end points, no formal sample size calculation was performed for this objective. The absolute area under the curve (AUC) after the meal was calculated for glucose, insulin, and acetaminophen, and the maximal acetaminophen concentration (C max ) and the time to reach C max (T max ) were noted. Finger arterial BP measurements were discarded in one patient randomized to lixisenatide because of failure of the sensor. Postprandial hypotension was defined as a fall in SBP of >20 mm Hg within 2 hours after the meal. 16 Statistical analyses were performed in the per protocol using SPSS Statistics for Windows, V22.0 (IBM Corp, Armonk, NY). For single-measured parameters, multivariable linear regression models were used to examine lixisenatide-induced effects compared with iGlu. To correct for potential between-group baseline differences, corresponding baseline values were added as independent variable. Within-group comparisons were analyzed using paired t tests or Wilcoxon signed-rank tests, as appropriate. Linear mixed model analyses were used to analyze both the between-and the within-group changes of repeatedly measured parameters. To assess the overall postbreakfast between-group treatment effect, treatment allocation, and the averaged corresponding baseline values (to adjust for baseline group differences) were added to the model. To assess overall postbreakfast within-group changes, treatment allocation was added as a categorical variable with the corresponding baseline values as reference category. To assess between-and within-group treatment effects at specific fasting and postbreakfast time points, time (treated as a categorical variable represented by dummy variables) and the interaction between treatment allocation and time were added to the model. Additional analyses were performed in which the influence of predefined parameters that could theoretically be of influence (AUC of acetaminophen, glucose, and insulin, and the LF/ HF-ratio, AIX@75, and CI) and differed between-or within-groups was assessed on postbreakfast SBP and DBP by adding the week 0 to week 8 difference as covariate. In addition, the interaction with RAS inhibitors was explored by adding RAS inhibitor use and the interaction between treatment allocation and RAS inhibitor use to the model. Spearman signed-rank test was used to assess associations. Data are presented as mean±SEM unless stated otherwise. Statistical significance was considered at a 2-sided P value <0.05.
Results
Patient Characteristics
The patient selection process has been described. 12 After exclusion of 1 patient in each treatment group because of preexistent atrial fibrillation, the final study population for the current analysis comprised of 18 patients in the iGlu arm and 16 patients in the lixisenatide-arm ( Figure characteristics are presented in Figures 1 and 2 ). These parameters also did not change within-groups, except for an SBP reduction in the iGlu arm (−6.9±2.8 mm Hg; P=0.015; Figure S2 ). After 4 weeks, there were no between or within-group differences in fasting SBP, DBP, or HR (P>0.05; data not shown).
Postbreakfast Measurements
BP and HR
At baseline in all patients, meal ingestion did not affect SBP, whereas DBP decreased at all but the last time point with a maximum difference of −2.5±0.8 mm Hg (P=0.002) at minute 55. Postprandial hypotension occurred in 3 patients, all subsequently randomized to iGlu. From baseline to week 8, lixisenatide compared with iGlu tended to increase overall SBP by +5.2±2.9 mm Hg (P=0.087) with a maximal difference of +10.2±3.7 mm Hg (P=0.007; Figures 1 and 3) . Within-group, lixisenatide increased SBP with an overall difference of 6.4±1.4 mm Hg (P<0.001) and maximally 9.1±2.9 (P=0.002; Figure S2 ). Figures 2 and 4) . Within-group, overall AIX@75 was higher with lixisenatide (P=0.005) and reduced with iGlu (P=0.026; Figure S2 ).
Heart Rate Variability
There were no between or within-group differences in the LF/HF-ratio overall (P=0.999) or at single time points after 8 weeks (Figures 2 and 4 ; Figure S2 ).
Metabolic and Hormonal Measurements
Lixisenatide and iGlu reduced HbA 1c from baseline to week 8 by 0.8±0.1% (P<0.001) and by 0.6±0.1% (P=0.001), respectively; there was no between-group difference (P>0.05; Table S1 ). Fasting glucose did not change after 8 weeks between or within treatment arms (P>0.05). Compared with iGlu, lixisenatide reduced the glucose AUC (P=0.001; Figure 5 ; Table 2 ). There were few measurements in the hypoglycemic range ( Figure 5 ). Lixisenatide compared with iGlu reduced the acetaminophen AUC (P<0.001) and C max (P<0.001), whereas increasing T max (P=0.010; Figure 5 ; Table 2 ). Insulin (endogenous and insulin glargine) reduced within-group with lixisenatide (P=0.003) and did not change with iGlu or between-groups. C-peptide decreased in both treatment arms with no between-group differences. There were no within or between-group differences in circulating postbreakfast angiotensin II, aldosterone, or catecholamine levels (Table S1 ).
Bodyweight and Body Composition
Numerically, bodyweight reduced with lixisenatide and increased with iGlu from baseline to week 8; the betweengroup difference of 1.4±0.6 kg reached statistical significance (P=0.022; Table S1 ). There were no differences in fasting or postbreakfast body water percentage. There was no betweengroup difference in fasting hematocrit, whereas postbreakfast hematocrit slightly increased with lixisenatide compared with iGlu (+0.01±0.01; P=0.045; Table S1 ).
Exploratory Analyses
In linear mixed models, the overall postbreakfast change in SBP was-to a large extent-explained by differences in acetaminophen AUC (mean difference reduced from 5.2±2. Pulse wave analysis and heart rate variability measurements at baseline and after 8-wk treatment with lixisenatide or insulin glulisine. Data are mean±SEM. AIX@HR75 indicates augmentation index normalized to heart rate of 75 bpm; and LF/HF-ratio, ratio of low frequency to high frequency.
In correlation analyses in all patients, the maximal changes in SBP and DBP at minute 85 associated with differences in acetaminophen AUC (r: −0.42; P=0.017 and r: −0.61; P<0.001, respectively) and acetaminophen levels at minute 90 (r: −0.38; P=0.034 and r: −0.58; P<0.001; Figure S3 ).
Discussion
In this secondary analysis of a randomized controlled trial, we demonstrated that prolonged treatment with lixisenatide compared with once-daily titrated iGlu does not affect fasting but increases overall postbreakfast BP, SVRI, and arterial stiffness in overweight T2DM patients on insulin glargine. The lixisenatide-induced vasopressor response was paralleled by a decrease in SVI, without changes in overall postbreakfast CI or cardiac sympathovagal balance (heart rate variability), or circulating catecholamines, angiotensin II, or aldosterone.
Lixisenatide did not affect fasting BP, despite inducing significant reductions in body weight and a sustained natriuretic effect after breakfast. 12 The neutral effect on fasting BP in the current study is in contrast with the reported 0.8 mm Hg SBP reduction in the 25-month landmark CVOT (Cardiovascular Outcome Trial) of lixisenatide (ELIXA [Evaluation of Lixisenatide in Acute Coronary Syndrome]), involving 6068 patients with T2DM and a recent acute coronary event. 25 The differential outcomes likely reflect the use of an active comparator (ie, iGlu lowered SBP within-group in our study), used sample size and duration of follow-up.
The lixisenatide-induced vasopressor response after breakfast is in line with previous studies, in which immediate GLP-1 or exenatide infusion attenuated the hypotensive response after oral ingestion of a meal or glucose in older volunteers 13 and T2DM patients. 13, 14 Notably, 8-week lixisenatide treatment did not affect mean 24 hours measured SBP or DBP in T2DM patients, 26 suggesting that the drug increases postprandial BP only during a single meal, without meaningful effects on 24-hour BP. In contrast, in our recent study in T2DM patients, 12-week treatment with the long-acting GLP-1RA did not affect postprandial systemic hemodynamics.
14 The neutral effect of liraglutide could be because of GLP-1R tachyphylaxis or druginduced activation of compensatory pathways with long-acting GLP-1RAs, which does not occur with short-acting GLP-1RAs. This results in waning effects on GER 26 (also resulting in higher postprandial glucose and insulin) and potentially likewise on other homeostatic systems that influence postprandial BP (see below). Alternatively, the differential response between lixisenatide and liraglutide on BP might involve structural diversities, as lixisenatide shares ≈50% amino acid sequence identity with mammalian GLP-1, whereas this is 97% for liraglutide. 12 The long-term clinical significance of a postbreakfast increase in BP with lixisenatide, and potentially also with other short-acting GLP-1RAs, is unknown. Observational studies suggest that arteriosclerosis is higher in elderly subjects that show a postprandial hypertensive response (defined as an SBP increase of >10 mm Hg within 30 minutes after a standardized lunch). 21 Moreover, although the clinical relevance of a transient postprandial AIX response is uncertain, a higher AIX in the fasting state is associated with increased cardiovascular and renal risk. 27, 28 Nevertheless, the ELIXA trial established the cardiovascular safety or neutrality of the drug, 25 implying that the changes do not importantly impact clinical outcome, potentially A B Figure 4 . Mean differences in pulse wave analysis and heart rate variability of 8-wk treatment with lixisenatide compared with insulin glulisine. Data are mean difference±SEM using linear mixed models to examine baselinecorrected lixisenatide-induced effects compared with insulin glulisine. *P<0.05 and **P<0.01. AIX@HR75 indicates augmentation index normalized to heart rate of 75 bpm; LF/HF-ratio, ratio of low frequency to high frequency; and PB, postbreakfast. because of their transient nature. Alternatively, although T2DM patients in ELIXA were relatively frail compared with other CVOTs, thus leaving little room for cardiovascular improvement, we can speculate that the observed vasopressor response partly explains the neutral effect on cardiovascular events with a short-acting GLP-1RA 25 compared with the cardiovascular benefits seen with the long-acting GLP-1RAs liraglutide 29 and semaglutide 30 and to lesser extent exenatide once-weekly. 31 Yet, in a specific T2DM population, a transient meal-related increase in BP could be clinically beneficial in the prevention of postprandial hypotension. Postprandial hypotension occurs in 0% to 70% of T2DM patients 32 and is associated with syncope, falls, angina, dizziness, light-headedness, visual disturbance, and increased mortality. 16 Interestingly, a proof-of-concept study in 15 healthy older subjects and 15 T2DM patients showed that acute administration of lixisenatide 10 µg markedly reduced GER of a 75 g glucose load and consequent glycemia, which was associated with attenuation of a rise in splanchnic blood flow and fall in postprandial SBP. 33 Notably, although we aimed for real-life effects in this study, the additional water ingestion as part of the protocol presumably led to higher postbreakfast BP estimates (see below), leading to potential overestimation of the corresponding cardiovascular and renal risk, and limiting adequate assessment of postprandial hypotension. Moreover, although the absence of morning antihypertensive medication permitted characterization of the true effects of the study drugs, results may be different when BP medication is present.
Numerous mechanisms may explain the observed increase in postbreakfast BP. As such, the lixisenatide-induced reduction in GER may have induced a direct vasopressor response. After a meal, the interaction of nutrients with the small intestine triggers a potential BP fall by splanchnic blood pooling and consequent reduction in venous return of blood to the heart, presumably mediated by neural and humoral factors. 16, 34 This response is greater when GER is relatively more rapid in T2DM. 35 However, postprandial BP lowering is attenuated by gastric distension, which increases muscle sympathetic nervous activity, vascular resistance and consequently BP (the so-called gastrovascular reflex). [15] [16] [17] Interestingly, ingestion of 480 mL water to induce gastric distension markedly increases SBP in patients with severe autonomic failure 36, 37 and older controls, 37 whereas it attenuates the hypotensive response to a meal in patients with postprandial hypotension. 38 Notably, HR decreased in these studies. [36] [37] [38] The effect is not explained by changes in intravascular volume or hormones, as it occurs within minutes after water ingestion and is almost completely abolished by ganglion blockage, indicating a neuronal pathway. 37 Adding guar gum to a meal also slows GER and small intestinal nutrient absorption leading to an attenuated postprandial BP reduction in older subjects and T2DM patients. 16 In the current study, we hypothesize that lixisenatide not only prevented a fall in postbreakfast BP by inhibiting the passage rate of nutrients through the stomach and small bowel but also augmented the gastrovascular reflex through nutrient-and water-induced gastric distension. Notably, the fast-acting neural pathways that may directly increase muscle sympathetic nerve activity do not necessarily associate with markers for cardiac and systemic SNS-activity, that is, the LF/ HF-ratio and circulating catecholamines, respectively, 17 which did not change in the current study. However, in studies that investigated the hemodynamic effects of intraduodenal glucose infusion, thereby bypassing the stomach, exogenous GLP-1 also attenuated the hypotensive response in healthy older subjects, 39 whereas exenatide even increased BP in T2DM patients. 18 These findings indicate that the effects of lixisenatide are, at least in part, mediated through mechanisms other than the gastrovascular reflex. First, it has been suggested that the GLP-1-related increase in HR raises CI and thereby BP. 3, 7, 8, 18, 40 Alternatively, GLP-1R-mediated inhibition of parasympathetic outflow or augmentation of SNS-activity could increase CI. 3, 5, 19, 41 Notably, preclinical studies also suggest that GLP-1R-stimulation increases HR and BP by directly augmenting sympathetic outflow from the central nervous system. 19, 41 However, although lixisenatide increased HR, the drug decreased SVI and did not affect CI or SNS-activity. This is in accordance with a direct effect of GLP-1RA on the sinoatrial node, as previously suggested, 9,42 whereas SNS-activation would be expected to lead to increased HR, SVI, and CI. Second, although the similar HbA 1c lowering in both treatment arms allowed for a clinically relevant comparison, one could speculate that postbreakfast glucose reduction with lixisenatide may have induced a vasoconstrictive response by activating the SNS. However, the number of glucose measurements in the hypoglycemic range was low and changes in glucose AUC did not explain postbreakfast changes in SBP or DBP. Moreover, SNS-activity did not change. Third, reduced postbreakfast insulin levels with lixisenatide because of inhibition of GER may have reduced insulin-dependent vasodilation 16 and increased vascular stiffness. 20 However, although AIX@75-to a minor extent-explained SBP, we were unable to identify a contributory role of insulin in our exploratory analyses. Notably, insulin resistance may have reduced the vasoactive effects of insulin in our population. 43 Finally, although GLP-1 and GLP-1RA generally have either neutral or vasodilating properties, 7, 39 we cannot exclude direct vasoconstrictive properties of lixisenatide, as was also suggested for acute exenatide infusion in a recent trial in T2DM patients. 9 Our study has several limitations apart from those discussed above. First, a noninvasive arterial BP monitoring device was used for determination of CI, although this is well validated against intra-arterial measurements.
14 Second, potential study drug-induced alterations in vascular tone may have affected estimations of CI, SVI, and SVRI from the finger arterial waveform. Third, AIX is an indirect marker of arterial stiffness. Fourth, we did not specifically measure muscle sympathetic nervous activity. Fifth, inherently to the linear mixed model technique, the overall effect of repeated measurements after the breakfast does not take the amount of time between separate measurements into account.
Perspectives
Here, we demonstrate that 8-week treatment with the shortacting GLP-1RA lixisenatide compared with once-daily titrated iGlu does not affect fasting, but increases postbreakfast BP in insulin glargine-treated overweight T2DM patients. This effect could, at least in part, be explained by reduced passage rate of nutrients and water, and activation of the gastrovascular reflex. Future studies should establish whether this response influences cardiovascular risk in individual patients or could aid in the prevention of postprandial hypotension.
